Adiponectin levels and the risk of hypertension: A systematic review and meta-analysis

Hypertension

Volumn 62, Issue 1, 2013, Pages 27-32

  Kim, Dae Hyun ^a,c   Kim, Chul ^d   Ding, Eric L ^b,c   Townsend, Mary K ^b   Lipsitz, Lewis A ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

adiponectin; blood pressure; hypertension; obesity; review; systematic

Indexed keywords

ADIPONECTIN;

BODY MASS; CARDIOVASCULAR RISK; CASE CONTROL STUDY; DOSE RESPONSE; EPIDEMIOLOGICAL DATA; FOLLOW UP; HUMAN; HYPERTENSION; META ANALYSIS; POPULATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REVIEW; SYSTEMATIC REVIEW;

ADIPONECTIN; BLOOD PRESSURE; HYPERTENSION; OBESITY; REVIEW, SYSTEMATIC;

ADIPONECTIN; BLOOD PRESSURE; HUMANS; HYPERTENSION; MORBIDITY; RISK FACTORS; WORLD HEALTH;

EID: 84880734090     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.113.01453     Document Type: Review

References (46)

1. Hui X, Lam KS, Vanhoutte PM, Xu A. Adiponectin and cardiovascular health: an update. Br J Pharmacol. 2012;165:574-590.
2. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116:1784-1792.
3. Goldstein BJ, Scalia R. Adiponectin: A novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab. 2004;89:2563-2568.
4. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagenlike factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun. 1996;221:286-289.
5. Magkos F, Sidossis LS. Recent advances in the measurement of adiponectin isoform distribution. Curr Opin Clin Nutr Metab Care. 2007;10:571-575.
6. Menzaghi C, Trischitta V, Doria A. Genetic influences of adiponectin on insulin resistance, type 2 diabetes, and cardiovascular disease. Diabetes. 2007;56:1198-1209.
7. Kawai T, Ohishi M, Takeya Y, Onishi M, Ito N, Yamamoto K, Oguro R, Kamide K, Rakugi H. Adiponectin single nucleotide polymorphism is a genetic risk factor for stroke through high pulse wave pressure: a cohort study. J Atheroscler Thromb. 2013;20:152-160.
8. Zhao T, Zhao J. Genetic effects of adiponectin on blood lipids and blood pressure. Clin Endocrinol (Oxf). 2011;74:214-222.
9. Wang ZV, Scherer PE. Adiponectin, cardiovascular function, and hypertension. Hypertension. 2008;51:8-14.
10. Ohashi K, Ouchi N, Matsuzawa Y. Adiponectin and hypertension. Am J Hypertens. 2011;24:263-269.
11. Yiannikouris F, Gupte M, Putnam K, Cassis L. Adipokines and blood pressure control. Curr Opin Nephrol Hypertens. 2010;19:195-200.
12. Watanabe S, Okura T, Kurata M, Irita J, Manabe S, Miyoshi K, Fukuoka T, Murakami K, Higaki J. The effect of losartan and amlodipine on serum adiponectin in Japanese adults with essential hypertension. Clin Ther. 2006;28:1677-1685.
13. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The newcastle-ottawa scale (nos) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical-epidemiology/ oxford.asp. Accessed April 9, 2013.
14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
15. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-1558.
16. Berlin JA, Longnecker MP, Greenland S. Meta-analysis of epidemiologic dose-response data. Epidemiology. 1993;4:218-228.
17. Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol. 1992;135:1301-1309.
18. Orsini N, Bellocco R, Greenland S. Generalized least squares for trend estimation of summarized dose-response data. Stata Journal. 2006;6:40-57.
19. Hong SJ, Park CG, Seo HS, Oh DJ, Ro YM. Associations among plasma adiponectin, hypertension, left ventricular diastolic function and left ventricular mass index. Blood Press. 2004;13:236-242.
20. Wildman RP, Mancuso P, Wang C, Kim M, Scherer PE, Sowers MR. Adipocytokine and ghrelin levels in relation to cardiovascular disease risk factors in women at midlife: longitudinal associations. Int J Obes (Lond). 2008;32:740-748.
21. Yilmaz MI, Sonmez A, Kilic S, Celik T, Bingol N, Pinar M, Mumcuoglu T, Ozata M. The association of plasma adiponectin levels with hypertensive retinopathy. Eur J Endocrinol. 2005;152:233-240.
22. Shankar A, Marshall S, Li J. The association between plasma adiponectin level and hypertension. Acta Cardiol. 2008;63:160-165.
23. Mallamaci F, Zoccali C, Cuzzola F, Tripepi G, Cutrupi S, Parlongo S, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y. Adiponectin in essential hypertension. J Nephrol. 2002;15:507-511.
24. Rahmouni K, Correia ML, Haynes WG, Mark AL. Obesity-associated hypertension: new insights into mechanisms. Hypertension. 2005;45:9-14.
25. Hall JE. The kidney, hypertension, and obesity. Hypertension. 2003;41(3 Pt 2):625-633.
26. Tanida M, Shen J, Horii Y, Matsuda M, Kihara S, Funahashi T, Shimomura I, Sawai H, Fukuda Y, Matsuzawa Y, Nagai K. Effects of adiponectin on the renal sympathetic nerve activity and blood pressure in rats. Exp Biol Med (Maywood). 2007;232:390-397.
27. Bassi M, do Carmo JM, Hall JE, da Silva AA. Chronic effects of centrally administered adiponectin on appetite, metabolism and blood pressure regulation in normotensive and hypertensive rats. Peptides. 2012;37:1-5.
28. Ouchi N, Ohishi M, Kihara S, et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension. 2003;42:231-234.
29. Ran J, Hirano T, Fukui T, Saito K, Kageyama H, Okada K, Adachi M. Angiotensin II infusion decreases plasma adiponectin level via its type 1 receptor in rats: an implication for hypertension-related insulin resistance. Metabolism. 2006;55:478-488.
30. Imai J, Katagiri H, Yamada T, Ishigaki Y, Ogihara T, Uno K, Hasegawa Y, Gao J, Ishihara H, Sasano H, Oka Y. Cold exposure suppresses serum adiponectin levels through sympathetic nerve activation in mice. Obesity (Silver Spring). 2006;14:1132-1141.
31. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, Yoshida D, Shimamoto K. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension. 2003;42:76-81.
32. Nowak Ł, Adamczak M, Wiecek A. Blockade of sympathetic nervous system activity by rilmenidine increases plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens. 2005;18:1470-1475.
33. Imatoh T, Miyazaki M, Momose Y, Tanihara S, Une H. Adiponectin levels associated with the development of hypertension: a prospective study. Hypertens Res. 2008;31:229-233.
34. Chow WS, Cheung BM, Tso AW, Xu A, Wat NM, Fong CH, Ong LH, Tam S, Tan KC, Janus ED, Lam TH, Lam KS. Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study. Hypertension. 2007;49:1455-1461.
35. Wang L, Manson JE, Gaziano JM, Liu S, Cochrane B, Cook NR, Ridker PM, Rifai N, Sesso HD. Plasma adiponectin and the risk of hypertension in white and black postmenopausal women. Clin Chem. 2012;58:1438-1445.
36. Duncan BB, Schmidt MI, Pankow JS, Bang H, Couper D, Ballantyne CM, Hoogeveen RC, Heiss G. Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes. 2004;53:2473-2478.
37. Xi B, He D, Wang Q, Xue J, Liu M, Li J. Common polymorphisms (rs2241766 and rs1501299) in the ADIPOQ gene are not associated with hypertension susceptibility among the Chinese. Mol Biol Rep. 2012;39:8771-8775.
38. International Consortium for Blood Pressure Genome-Wide Association S. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478:103-109.
39. Yudkin JS, Eringa E, Stehouwer CD. "Vasocrine" signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet. 2005;365:1817-1820.
40. Asferg C, Mogelvang R, Flyvbjerg A, Frystyk J, Jensen JS, Marott JL, Appleyard M, Jensen GB, Jeppesen J. Leptin, not adiponectin, predicts hypertension in the Copenhagen City Heart Study. Am J Hypertens. 2010;23:327-333.
41. Olszanecka A, Pośnik-Urbańska A, Kawecka-Jaszcz K, Czarnecka D, Fedak D. Adipocytokines and blood pressure, lipids and glucose metabolism in hypertensive perimenopausal women. Kardiol Pol. 2010;68:753-760.
42. Patel JV, Lim HS, Dubb K, Hughes EA, Lip GY. Circulating levels of adiponectin, leptin, and tumour necrosis factor alpha in hypertension. Ann Med. 2009;41:291-300.
43. Miettinen OS. The "case-control" study: valid selection of subjects. J Chronic Dis. 1985;38:543-548.
44. Hankinson SE, Manson JE, Spiegelman D, Willett WC, Longcope C, Speizer FE. Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. Cancer Epidemiol Biomarkers Prev. 1995;4:649-654.
45. Inoue T, Kotooka N, Morooka T, Komoda H, Uchida T, Aso Y, Inukai T, Okuno T, Node K. High molecular weight adiponectin as a predictor of long-term clinical outcome in patients with coronary artery disease. Am J Cardiol. 2007;100:569-574.
46. Lara-Castro C, Luo N, Wallace P, Klein RL, Garvey WT. Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes. 2006;55:249-259. Center